Latest News and Press Releases

Mr. Jafar is a distinguished international business leader and co-founder of the Loulou Foundation OXFORD, UK and CLEVELAND, Ohio, US, 29 April 2025 – The Oxford-Harrington Rare Disease Centre...

Er-Kim broadens drug distribution for novel rare endocrinology disease therapies in CEE and Eurasian markets

DURHAM, N.C., May 20, 2024 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare...

DURHAM, N.C., May 08, 2024 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare...

Expansion of the AER-901 development program to include pulmonary hypertension associated with interstitial lung disease (PH-ILD) builds on the company’s existing program in pulmonary arterial...

DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious cardiopulmonary...

AER-901 (inhaled imatinib), a potential reverse-remodeling therapy, is being developed to address unmet need for PAH treatments that target pulmonary vascular remodeling while supporting ease-of-use...

Lisa Yañez Incoming Chief Executive OfficerAerami Therapeutics DURHAM, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Aerami Therapeutics Holdings, Inc (“Aerami”), a clinical-stage biopharmaceutical...

DURHAM, N.C., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. (“Aerami” or the “Company”) a clinical stage biopharmaceutical company developing inhaled therapies to treat severe...

Majority of potential study participants have been pre-screened EB-101 successfully manufactured at Abeona and transplanted at Stanford University Medical Center NEW YORK and CLEVELAND, March 17,...